<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Inst of Molecular &amp; Cellular Biology</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FAB06145-89EB-432F-A39D-75803C4D7340"><gtr:id>FAB06145-89EB-432F-A39D-75803C4D7340</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Turner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EBA26F39-5359-49BF-BD3D-A4FB6C93AA76"><gtr:id>EBA26F39-5359-49BF-BD3D-A4FB6C93AA76</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Hooper</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9824728"><gtr:id>7855C78E-9F47-42C8-B7C6-864D7F94FA7E</gtr:id><gtr:title>Amyloid precursor protein and prion protein: cellular functions, processing and roles in neurodegeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9824728</gtr:grantReference><gtr:abstractText>Alzheimer?s disease is a debilitating disorder that affects a high proportion of the elderly population of this country. Individuals with Alzheimer?s suffer from memory loss, disorientation and impairment of judgement and reasoning. Transmissible spongiform encephalopathies (TSEs) or prion diseases, such as Creutzfeldt-Jakob disease (CJD), are relatively rare but have received much attention in recent years because of the potential number of individuals in the UK affected following the epidemic of bovine spongiform encephalopathy (BSE). A major issue of current concern is that blood donors may be subclinically infected with the BSE agent and could potentially transmit variant CJD via blood transfusion to healthy individuals. The primary aim of our work is to provide more information on the two key proteins, Alzheimer?s amyloid precursor protein and prion protein, that are implicated in these diseases. Through a molecular and cell biological approach our work will provide information on the normal cellular roles of these proteins, the way in which they are normally processed, and what goes wrong to these processes in the disease situation. The results from our work may aid in the identification of novel therapeutic targets which could subsequently be exploited as potential treatments for these diseases.</gtr:abstractText><gtr:technicalSummary>Alzheimers disease (AD) is the major neurodegenerative disease of the ageing brain that is extremely complex and ill understood but which poses an ever-expanding burden on the Health Service in an ageing population. In contrast, transmissible spongiform encephalopathies (TSEs), such as Creutzfeldt-Jakob disease (CJD), are relatively rare but have received much attention in recent years because of the potential number of individuals in the UK affected following the epidemic of bovine spongiform encephalopathy (BSE). AD is characterised by the deposition in the brain of senile plaques consisting predominantly of the amyloid-beta (Abeta) peptide that is derived by proteolytic cleavage of the amyloid precursor protein (APP). TSEs are characterised by the conformational conversion of the normal cellular form of the prion protein, PrPC, to a pathogenic form PrPSc. In addition to APP and PrP being critically involved in neurodegenerative disorders, there are strong similarities between the proteolytic processing, cellular location and function of the two proteins, as well as neuropathological evidence indicating an association between AD and prion diseases. The overall aim of this proposal is to elucidate further both the normal and pathological roles of PrP, APP and their metabolic products. The specific objectives are: (a) to evaluate the effect of AD therapeutic compounds on the expression and activity of the alpha-secretases that cleave APP and prevent the formation of Abeta; (b) to investigate the role of different lipid rafts in the isoform distribution and amyloidogenic processing of APP; (c) to identify the PrP lipid raft targeting molecule and evaluate its role in PrP metabolism; (d) to investigate the cellular and molecular interaction between PrP and the beta-secretase cleavage of APP; (e) to evaluate the role of proteolytic processing in the metabolism of PrPC and its conversion to PrPSc; (f) to investigate the role and regulation of Abeta catabolising peptidases in the pathogenesis of AD; (g) to evaluate the role of APP isoforms in the cellular response to oxidative stress; and (h) to identify extracellular ligands and/or receptors for APP. The results from this inter-related programme of work will not only provide novel information on the normal and pathogenic roles of APP and PrP, but may also identify new therapeutic targets and common mechanisms for AD and TSEs.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2467127</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Roslin Institute</gtr:department><gtr:description>Leeds-Edinburgh</gtr:description><gtr:id>A6340C3C-B06D-4ED0-A1F3-E9B0FE787050</gtr:id><gtr:impact>Pilot grant awarded by the Alzheimer's Research Trust to establish a new mouse model for Alzheimer's disease</gtr:impact><gtr:outcomeId>maQEHwA5EYW-1</gtr:outcomeId><gtr:partnerContribution>Initial data has been generated which is the subject of a submitted publication.</gtr:partnerContribution><gtr:piContribution>Ongoing intellectual input to the design of experiments and writing of grant applications based on findings arising from research in Leeds</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Roslin Institute</gtr:department><gtr:description>Leeds-Edinburgh</gtr:description><gtr:id>0CFC7884-5BF6-46EE-8AFF-3CE73F639E8E</gtr:id><gtr:impact>Pilot grant from the Alzheimer's Research Trust and a submitted publication.
Publication in PLOS ONE</gtr:impact><gtr:outcomeId>HPxVNgRLTCA-1</gtr:outcomeId><gtr:partnerContribution>Expertise in animal models</gtr:partnerContribution><gtr:piContribution>Intellectual input into the design of experiments and analysis of results based on work originating from Leeds.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media - glypican</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B0F5241C-D3AA-4413-B756-66C1A638A915</gtr:id><gtr:impact>Press release issued by University that was taken up by several agencies.

No subsequent impact</gtr:impact><gtr:outcomeId>E80B8471062</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mount School York</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5E9A2F59-C6B7-4675-9DCE-730CDB77D754</gtr:id><gtr:impact>Talk to pupils about Alzheimer's disease and our ongoing research.

No subsequent impact</gtr:impact><gtr:outcomeId>71DC101755D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media (as a channel to the public)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>291FB6FE-BFAB-492D-8D39-9CDB3366BDC5</gtr:id><gtr:impact>Press releases issues by University, ARUK or MRC which was taken up by numerous agencies.

Increased awareness of and impact of our research. Invitations to speak on local and national radio.</gtr:impact><gtr:outcomeId>1505F50723F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ART Project Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>04EC88E1-B69F-4A0F-86A2-D3C2B2C5E350</gtr:id><gtr:outcomeId>D2C9079F49B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0802189</gtr:fundingRef><gtr:id>7A6E314F-B3D4-45DB-B808-89C5E4C6B90E</gtr:id><gtr:outcomeId>1F83CF541DA0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Cell lines transfected with various constructs of the prion protein or amyloid precursor protein.</gtr:description><gtr:id>E42EEC7D-3655-43B0-9CFA-2E46B7E8D5F4</gtr:id><gtr:impact>Various publications resulting from use of cells</gtr:impact><gtr:outcomeId>D48A008F50D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transfected cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PrP null mice have been crossed with the J20 mouse model of Alzheimer's disease</gtr:description><gtr:id>A2F2EC59-AD5D-4972-B354-F478C2410C1D</gtr:id><gtr:impact>A publication describing the effect of deletion of PrP on APP processing.</gtr:impact><gtr:outcomeId>rsxkEiuv7ML</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PrP null - J20 mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Various mammalian cell lines transfected with constructs of APP, PrP and other proteins involved in Alzheimer's disease.</gtr:description><gtr:id>CED8DB49-DCB2-4CA9-B010-7253BF11BEB8</gtr:id><gtr:impact>These cell lines have contributed significantly to publications arising from our research group and that of others.</gtr:impact><gtr:outcomeId>cWoWk646P15</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transfected cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PrP null mice have been crossed with the J20 Alzheimer's model mouse.</gtr:description><gtr:id>FBA74794-E464-46C1-9CB4-EDE46016E9D5</gtr:id><gtr:impact>A publication reporting the results of depletion of PrP on APP processing.</gtr:impact><gtr:outcomeId>RR1RLsS8ndb</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PrP null J20 mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E6F68FB2-63E1-4B40-B43F-B7EEACABC3A8</gtr:id><gtr:title>The prion protein and lipid rafts.</gtr:title><gtr:parentPublicationTitle>Molecular membrane biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9895abc74f0b6514ec53d171e2962b0"><gtr:id>e9895abc74f0b6514ec53d171e2962b0</gtr:id><gtr:otherNames>Taylor DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0968-7688</gtr:issn><gtr:outcomeId>6E08BBE0B25</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ACA62BF-A8DF-4A91-B80C-48D8C9BCC47E</gtr:id><gtr:title>Cellular prion protein protects against reactive-oxygen-species-induced DNA damage.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541d949c24596c6bec271f38c5bec152"><gtr:id>541d949c24596c6bec271f38c5bec152</gtr:id><gtr:otherNames>Watt NT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>74D5AEFF825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2DDA405-1317-4988-9DA0-EFBCEFC29E6F</gtr:id><gtr:title>Prion protein and Alzheimer disease.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5388a44cf25ecdd72492f9ae1af10ba"><gtr:id>a5388a44cf25ecdd72492f9ae1af10ba</gtr:id><gtr:otherNames>Kellett KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>8CD659BEA85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>783FE68F-E1D7-4874-9AEE-4E3A9EA3B5B7</gtr:id><gtr:title>Mechanism of the metal-mediated endocytosis of the prion protein.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b796cc35cf0d7f1ec9412abbbbca713"><gtr:id>3b796cc35cf0d7f1ec9412abbbbca713</gtr:id><gtr:otherNames>Hooper NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>D6BC15A9125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91E982D5-D813-477B-97C3-9850AB75A198</gtr:id><gtr:title>Emerging therapeutics for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Expert review of neurotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cfeffc5253202ae9e868dd20253f335"><gtr:id>0cfeffc5253202ae9e868dd20253f335</gtr:id><gtr:otherNames>Vardy ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1473-7175</gtr:issn><gtr:outcomeId>378D4D9271F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7712594C-3489-40DD-89D7-390F507D5120</gtr:id><gtr:title>Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e28bbb729b17ec97877b2004857fbb2"><gtr:id>7e28bbb729b17ec97877b2004857fbb2</gtr:id><gtr:otherNames>Whyteside AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>0B63034915E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDFF9DCD-BE1D-46E1-930E-53B7C85E0C90</gtr:id><gtr:title>Expression of NEP2, a soluble neprilysin-like endopeptidase, during embryogenesis in Drosophila melanogaster.</gtr:title><gtr:parentPublicationTitle>Peptides</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c71a7ac180f82d8911b06bc9b6701485"><gtr:id>c71a7ac180f82d8911b06bc9b6701485</gtr:id><gtr:otherNames>Bland ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0196-9781</gtr:issn><gtr:outcomeId>4C64E6E17D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C76A71EB-9701-4D74-AF19-3064E27FEC49</gtr:id><gtr:title>Membrane raft actin deficiency and altered Ca2+-induced vesiculation in stomatin-deficient overhydrated hereditary stomatocytosis.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5559934e5dcff2671186da354ae3b2e4"><gtr:id>5559934e5dcff2671186da354ae3b2e4</gtr:id><gtr:otherNames>Wilkinson DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>10AEC029C27</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35A57DDA-50D4-436C-9874-59A594DE78E7</gtr:id><gtr:title>Glypican-1 mediates both prion protein lipid raft association and disease isoform formation.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9895abc74f0b6514ec53d171e2962b0"><gtr:id>e9895abc74f0b6514ec53d171e2962b0</gtr:id><gtr:otherNames>Taylor DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>E475272F5BE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE94727C-BE96-4E27-962A-DA184AB203E3</gtr:id><gtr:title>Protective effect of prion protein via the N-terminal region in mediating a protective effect on paraquat-induced oxidative injury in neuronal cells.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcd4d5651335d043cffdccf9c0ef1ec1"><gtr:id>bcd4d5651335d043cffdccf9c0ef1ec1</gtr:id><gtr:otherNames>Dupiereux I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn><gtr:outcomeId>46F21FF9BCB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EDC5BF4-95FF-4FF9-8BBD-E62A4DB6B420</gtr:id><gtr:title>Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9895abc74f0b6514ec53d171e2962b0"><gtr:id>e9895abc74f0b6514ec53d171e2962b0</gtr:id><gtr:otherNames>Taylor DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>A7E549ED372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B50504C9-6453-4DBE-BEA7-EFD03AAB5F55</gtr:id><gtr:title>Contamination of nuclear fractions with plasma membrane lipid rafts.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/070dc2007d75c9e085f7fd8ffde3f691"><gtr:id>070dc2007d75c9e085f7fd8ffde3f691</gtr:id><gtr:otherNames>Say YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>ECEA261FF87</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F105BA5-D2CE-45CA-843B-BA928FF55673</gtr:id><gtr:title>Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes.</gtr:title><gtr:parentPublicationTitle>Neurochemical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfa7a314078079dc98cfe01ecea37d7a"><gtr:id>bfa7a314078079dc98cfe01ecea37d7a</gtr:id><gtr:otherNames>Fisk L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0364-3190</gtr:issn><gtr:outcomeId>21E7B2D9FA9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B9E29A9-6123-47BA-88E7-BD9CA112C346</gtr:id><gtr:title>The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5dd409cf763310de09deaf372d1118b"><gtr:id>a5dd409cf763310de09deaf372d1118b</gtr:id><gtr:otherNames>Belyaev ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_13728_28_20961856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFDCD6BF-C808-498C-BED2-2515A6DC18ED</gtr:id><gtr:title>Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5dd409cf763310de09deaf372d1118b"><gtr:id>a5dd409cf763310de09deaf372d1118b</gtr:id><gtr:otherNames>Belyaev ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>BE157462C14</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71E7E968-4FE9-422A-822D-A0C188D3EF02</gtr:id><gtr:title>Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c76c2ec5fcb5dbc1ccd7d6a565fae16"><gtr:id>9c76c2ec5fcb5dbc1ccd7d6a565fae16</gtr:id><gtr:otherNames>Parkin ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>9E3D8E72D16</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6608773-939E-4E80-B687-18221C6722DA</gtr:id><gtr:title>Regulation of endothelin-converting enzyme-1 expression in human neuroblastoma cells.</gtr:title><gtr:parentPublicationTitle>Experimental biology and medicine (Maywood, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfa7a314078079dc98cfe01ecea37d7a"><gtr:id>bfa7a314078079dc98cfe01ecea37d7a</gtr:id><gtr:otherNames>Fisk L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1535-3699</gtr:issn><gtr:outcomeId>FC43ACA9ADF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95EC6F25-FD56-4509-B69C-9D2F433852B8</gtr:id><gtr:title>New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40a7a07c6b4fe9c1ea22d572a2f685"><gtr:id>fe40a7a07c6b4fe9c1ea22d572a2f685</gtr:id><gtr:otherNames>Turner AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>883CE76594C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C2CED17-6FF7-4F6D-B10F-B32377B644CF</gtr:id><gtr:title>Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins.</gtr:title><gtr:parentPublicationTitle>Seminars in cell &amp; developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9895abc74f0b6514ec53d171e2962b0"><gtr:id>e9895abc74f0b6514ec53d171e2962b0</gtr:id><gtr:otherNames>Taylor DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1084-9521</gtr:issn><gtr:outcomeId>29446425844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB1F5C1-6534-4849-8FC6-5FF0FC2DEC86</gtr:id><gtr:title>The involvement of lipid rafts in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Molecular membrane biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a095883454514497071f58b4e8a865b"><gtr:id>9a095883454514497071f58b4e8a865b</gtr:id><gtr:otherNames>Cordy JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0968-7688</gtr:issn><gtr:outcomeId>A8132D3ED17</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56BF46E9-46F4-4453-9590-D64AEA826D24</gtr:id><gtr:title>Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Current Alzheimer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d44e15c61465b5e28d55e404cebd2b6"><gtr:id>0d44e15c61465b5e28d55e404cebd2b6</gtr:id><gtr:otherNames>Nalivaeva NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1567-2050</gtr:issn><gtr:outcomeId>02DE6019B9C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34573D59-08BD-405F-B1D8-6A4A15669BC2</gtr:id><gtr:title>A new take on prions: preventing Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b796cc35cf0d7f1ec9412abbbbca713"><gtr:id>3b796cc35cf0d7f1ec9412abbbbca713</gtr:id><gtr:otherNames>Hooper NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn><gtr:outcomeId>E5A0BFB6B3B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5049AD1E-0B29-4ACA-8C8C-6DE030D5809C</gtr:id><gtr:title>Sodium valproate: an old drug with new roles.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d44e15c61465b5e28d55e404cebd2b6"><gtr:id>0d44e15c61465b5e28d55e404cebd2b6</gtr:id><gtr:otherNames>Nalivaeva NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>D75F8307140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AE815C8-571D-453C-BC4F-E8EB2DA30DDD</gtr:id><gtr:title>Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dea58225bb19e3ca036aecf0e8d76496"><gtr:id>dea58225bb19e3ca036aecf0e8d76496</gtr:id><gtr:otherNames>Griffiths HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>ESebJsQtuAe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C4D761A-AD8B-4FEF-A8AB-197767C9FFA1</gtr:id><gtr:title>Emerging and potential therapies for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dea58225bb19e3ca036aecf0e8d76496"><gtr:id>dea58225bb19e3ca036aecf0e8d76496</gtr:id><gtr:otherNames>Griffiths HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>535B9827BF4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF1EE3B2-4A91-4523-BF92-60F4BCB1B09B</gtr:id><gtr:title>Proteinase dysbalance in pathology: the neprilysin (NEP) and angiotensin-converting enzyme (ACE) families.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular biology (Noisy-le-Grand, France)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40a7a07c6b4fe9c1ea22d572a2f685"><gtr:id>fe40a7a07c6b4fe9c1ea22d572a2f685</gtr:id><gtr:otherNames>Turner AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0145-5680</gtr:issn><gtr:outcomeId>BFF9AA4D18F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDC56BB2-79D8-447C-8458-6B3FDCCC2C77</gtr:id><gtr:title>alpha-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f336a4f1ccd980ab7558002a6c4ef02"><gtr:id>2f336a4f1ccd980ab7558002a6c4ef02</gtr:id><gtr:otherNames>Walmsley AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>8A8807BD169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBC08357-C658-430E-A321-6C8A0E961817</gtr:id><gtr:title>Prion protein facilitates uptake of zinc into neuronal cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541d949c24596c6bec271f38c5bec152"><gtr:id>541d949c24596c6bec271f38c5bec152</gtr:id><gtr:otherNames>Watt NT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13728_28_23072804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>505721EB-C9B9-4E63-A8C8-6E8CFD8B68F4</gtr:id><gtr:title>Bioinformatic analysis of the neprilysin (M13) family of peptidases reveals complex evolutionary and functional relationships.</gtr:title><gtr:parentPublicationTitle>BMC evolutionary biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c71a7ac180f82d8911b06bc9b6701485"><gtr:id>c71a7ac180f82d8911b06bc9b6701485</gtr:id><gtr:otherNames>Bland ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-2148</gtr:issn><gtr:outcomeId>F829C52D314</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9824728</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>